{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T18:45:50Z","timestamp":1767033950714},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T00:00:00Z","timestamp":1529452800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12931-018-0830-z","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T07:12:59Z","timestamp":1529478779000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Indacaterol\/glycopyrronium versus salmeterol\/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study"],"prefix":"10.1186","volume":"19","author":[{"given":"Antonio R.","family":"Anzueto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Kostikas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Larbig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jadwiga A.","family":"Wedzicha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,20]]},"reference":[{"key":"830_CR1","volume-title":"And prevention of chronic obstructive pulmonary disease","author":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)","year":"2018","unstructured":"Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management. In: And prevention of chronic obstructive pulmonary disease; 2018."},{"key":"830_CR2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.05.020415","volume":"5","author":"D Adeloye","year":"2015","unstructured":"Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, Nair H, Gasevic D, Sridhar D, Campbell H, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5:020415.","journal-title":"J Glob Health"},{"key":"830_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199\u2013209.","journal-title":"Lancet Respir Med"},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12931-017-0622-x","volume":"18","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, et al. Efficacy and safety of direct switch to indacaterol\/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18:140.","journal-title":"Respir Res"},{"key":"830_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/COPD.S133307","volume":"12","author":"AR Anzueto","year":"2017","unstructured":"Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R. The effect of indacaterol\/glycopyrronium versus tiotropium or salmeterol\/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325\u201337.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2147\/COPD.S101612","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413\u201324.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"830_CR7","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33:2188\u201399.","journal-title":"Adv Ther"},{"key":"830_CR8","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42:1484\u201394.","journal-title":"Eur Respir J"},{"key":"830_CR9","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1183\/09031936.00124013","volume":"43","author":"DA Mahler","year":"2014","unstructured":"Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599\u2013609.","journal-title":"Eur Respir J"},{"key":"830_CR10","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMoa1516385","volume":"374","author":"JA Wedzicha","year":"2016","unstructured":"Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222\u201334.","journal-title":"N Engl J Med"},{"key":"830_CR11","doi-asserted-by":"crossref","unstructured":"Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, Banerji D. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;(1):51\u201360.","DOI":"10.1016\/S2213-2600(12)70052-8"},{"key":"830_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jama.2009.2017","volume":"303","author":"G Tomlinson","year":"2010","unstructured":"Tomlinson G, Detsky AS. Composite end points in randomized trials: there is no free lunch. JAMA. 2010;303:267\u20138.","journal-title":"JAMA"},{"key":"830_CR13","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jclinepi.2006.10.020","volume":"60","author":"I Ferreira-Gonzalez","year":"2007","unstructured":"Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, Walter SD, Guyatt GH. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007;60:651\u20137.","journal-title":"J Clin Epidemiol"},{"key":"830_CR14","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa021322","volume":"350","author":"BR Celli","year":"2004","unstructured":"Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005\u201312.","journal-title":"N Engl J Med"},{"key":"830_CR15","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1164\/rccm.200902-0271OC","volume":"180","author":"RC Jones","year":"2009","unstructured":"Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180:1189\u201395.","journal-title":"Am J Respir Crit Care Med"},{"key":"830_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S0140-6736(09)61301-5","volume":"374","author":"MA Puhan","year":"2009","unstructured":"Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG, Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, Held U. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374:704\u201311.","journal-title":"Lancet"},{"key":"830_CR17","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1183\/09031936.00058713","volume":"43","author":"D Stolz","year":"2014","unstructured":"Stolz D, Kostikas K, Blasi F, Boersma W, Milenkovic B, Lacoma A, Louis R, Aerts JG, Welte T, Torres A, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the \"BODE-A\" index. Eur Respir J. 2014;43:397\u2013408.","journal-title":"Eur Respir J"},{"key":"830_CR18","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1183\/13993003.01485-2015","volume":"47","author":"L Boeck","year":"2016","unstructured":"Boeck L, Soriano JB, Brusse-Keizer M, Blasi F, Kostikas K, Boersma W, Milenkovic B, Louis R, Lacoma A, Djamin R, et al. Prognostic assessment in COPD without lung function: the B-AE-D indices. Eur Respir J. 2016;47:1635\u201344.","journal-title":"Eur Respir J"},{"key":"830_CR19","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1164\/rccm.201701-0193OC","volume":"195","author":"N Roche","year":"2017","unstructured":"Roche N, Chapman KR, Vogelmeier CF, Herth FJF, Thach C, Fogel R, Olsson P, Patalano F, Banerji D, Wedzicha JA. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med. 2017;195:1189\u201397.","journal-title":"Am J Respir Crit Care Med"},{"key":"830_CR20","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/COPD.S108758","volume":"11","author":"GT Ferguson","year":"2016","unstructured":"Ferguson GT, Karpel JP, Clerisme-Beaty E, Gronke L, Voss F, Buhl R. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO((R)) and OTEMTO((R)) studies: a subgroup analysis by age. Int J Chron Obstruct Pulmon Dis. 2016;11:2701\u201310.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"830_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1080\/15412555.2017.1324837","volume":"14","author":"I Tsiligianni","year":"2017","unstructured":"Tsiligianni I, Mezzi K, Fucile S, Kostikas K, Shen S, Banerji D, Fogel R. Response to Indacaterol\/Glycopyrronium (IND\/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE program. COPD. 2017;14:375\u201381.","journal-title":"COPD"},{"key":"830_CR22","first-page":"132","volume":"4","author":"PW Jones","year":"2017","unstructured":"Jones PW, Gelhorn H, Karlsson N, Menjoge S, Mullerova H, Rennard SI, Tal-Singer R, Wilson H, Merrill D, Tabberer M. Baseline severity as predictor of change in St George's respiratory questionnaire scores in trials of long-acting bronchodilators with COPD patients. Chronic Obstr Pulm Dis. 2017;4:132\u201340.","journal-title":"Chronic Obstr Pulm Dis"},{"key":"830_CR23","doi-asserted-by":"crossref","unstructured":"Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fageras M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117\u201326.","DOI":"10.1016\/S2213-2600(18)30006-7"},{"key":"830_CR24","doi-asserted-by":"crossref","unstructured":"Papi A, Kostikas K, Wedzicha JA, Vogelmeier CF, Roche N, Shen S, Banerji D, Fogel R, Patalano F, Chapman KR. Dual bronchodilation response by exacerbation history and eosinophilia in the FLAME study. Am J Respir Crit Care Med.2018;197(9):1223\u20136.","DOI":"10.1164\/rccm.201709-1822LE"},{"key":"830_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1136\/thorax.57.10.847","volume":"57","author":"GC Donaldson","year":"2002","unstructured":"Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847\u201352.","journal-title":"Thorax"},{"key":"830_CR26","doi-asserted-by":"crossref","unstructured":"Naya I, Tombs L, Mullerova H, Compton C, Jones P. Long-term outcome following first clinically important deterioration in COPD. Eur Respir J. 2016;(48):PA304.","DOI":"10.1183\/13993003.congress-2016.PA304"},{"key":"830_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1056\/NEJMoa1407154","volume":"371","author":"H Magnussen","year":"2014","unstructured":"Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285\u201394.","journal-title":"N Engl J Med"},{"key":"830_CR28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454\u201363.","journal-title":"N Engl J Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-018-0830-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-018-0830-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,19]],"date-time":"2019-06-19T19:06:33Z","timestamp":1560971193000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-018-0830-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,20]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1186\/s12931-018-0830-z","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,20]]},"assertion":[{"value":"12 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study complied with the Declaration of Helsinki and the International Conference on Harmonisation and Good Clinical Practice guidelines. The protocol was approved by the regulatory authority for each country (where applicable) and an independent ethics committee at each center. All patients provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AA has received honoraria for consultant services and speaking from Novartis, AstraZeneca, Boehringer Ingelheim, Sunovion Pharma, and GlaxoSmithKline. JAW has received no honoraria for lectures, consultant services and\/or advisory boards. She has received research grants from Novartis, AstraZeneca, Boehringer Ingelheim, Johnson and Johnson, Sunovion Pharma, GlaxoSmithKline. KK is an employee and shareholder at Novartis Pharma AG. KK has previously received honoraria for speeches and consulting services from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN and Takeda, outside the submitted work. None of the authors received any compensation for the development of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"121"}}